Claris Injectables, a subsidiary of India-based Claris Lifesciences Limited, earned Food and Drug Administration approval for its flumazenil injectable medication.
Flumazenil reverses the drowsiness and sedation that occurs when patients take a class of psychoactive drugs called benzodiazepines. The estimated U.S. market size for the drug is about $4 million.
Claris currently has 16 drug approvals, with 23 pending. The company expects more market approvals before the end of the year.